anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Neutrophils (PMN) can migrate along gradients of chemoattractants across endothelial monolayers to sites of inflammation and infection. This chemotaxis through endothelial cell borders is involved in several acute and chronic inflammatory diseases, however our understanding of the role of endothelial second messengers in the regulation of leukocyte emigration is still incomplete. We investigated this using an in vitro model of neutrophil migration across human umbilical vein endothelial cells (HUVECs) and human microvascular endothelial cells (HMECs) on cell culture inserts. We report that activation of endothelial protein kinase C (PKC) by both phorbol myristate acetate (PMA) and Bryostatin-1 (a potent PKCδ and c activator) can completely abolish neutrophil migration mediated by both endothelial TNF-α stimulation and a leukotriene B4 (LTB 4 ) gradient. PMA protected against LTB 4  induced PMN transmigration for at least 24 hours in HMECs and HUVECs. Bryostatin-1 protected PMN migration for at least 24 hours in HMECs and at least 48 hours in HUVECs. Pretreatment with Go-6983 (PKCα, β, and δ inhibitor) before the addition of Bryostatin-1 restored the loss of LTB 4  induced neutrophil migration, while pretreatment with GO-6976 (PKCα and β inhibitor) did not. In addition using PKCδ and ε specific small interfering RNA, we were able to show that PKCδ, but not ε was at least mostly responsible for the loss of neutrophil migration in response to LTB 4 . Taken together, these observations suggest that activation of endothelial PKCδ could be therapeutic in the treatment of various inflammatory disorders characterized by enhanced neutrophil infiltration. 
     This invention relates to pharmaceutical compositions, particularly pharmaceutical compositions comprising bryostatin-1 and substituted derivatives of bryostatin-1, thereof as pharmaceuticals for inhibition of inflammation, and for use in combating arteriosclerosis, diseases of the cardiovascular system, of the central nervous system and prior to/following organ transplantation, ischemia. The invention relates to methods for treating leukocyte dependent injury in chronic inflammatory diseases, and injury from transplantation mediated organ stress. The method involves injecting bryostatin-1 into patients with the inflammatory condition, treating the skin with bryostatin-1, or perfusing organs with bryostatin-1 prior to transplantation/cold storage. Activation of protein kinase Cd (PKCd) results in a near complete blockade of leukocyte infiltration which is the result of stabilization of the microvascular (endothelial) barrier.
The pharmaceutical compositions described comprise a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer for oral delivery. Some pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer (e.g. a salt of a medium chain fatty acid) and a lipophilic medium. The pharmaceutical compositions may be enteric-coated. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. The methods of treatment described herein increase the level of iron in the bloodstream of a subject by administering to the subject an effective amount of an oral composition of a ferric iron compound.
The invention belongs to the fields of functions and applications of gene and protein, and relates to Flotilli-2 as a target in screening nasopharyngeal carcinoma metastasis inhibiting drugs and an application of the Flotillin-2. The invention provides a target for screening nasopharyngeal carcinoma metastasis inhibiting drugs, wherein the target is Flotillin-2. The invention also provides an application of the Flotillin-2 as a drug target in screening nasopharyngeal carcinoma metastasis inhibiting drugs. The invention also provides a drug for inhibiting nasopharyngeal carcinoma metastasis, which takes the Flotillin-2 as a target. The drug is siRNA of Flotillin-2. The invention discloses the relation between the Flotillin-2 (Flot2) and a TGF-beta signal path in nasopharyngeal carcinoma as well as effects of the Flot2 and the TGF-beta signal path in nasopharyngeal carcinoma metastasis for the first time. In the nasopharyngeal carcinoma, the Flot2 is an independent predictive factor of patient poor prognosis, an important component of the TGF-beta signal path and an indispensable important node in a process of stimulating emergency medical treatment (EMT). Silent Flot2 may become one of important means of resisting EMT caused by TGF-beta. Therefore, the invention provides a theoretical foundation and a clinical base for researching a new target and a new strategy in inhibiting nasopharyngeal carcinoma metastasis.
The invention provides a PTEN subtype protein PTEN gamma participating in regulation of telomere length and application thereof, belonging to the technical field of functional proteins. PTEN subtype protein PTEN gamma which participates in the regulation of telomere length, and the amino acid sequence is shown as SEQ ID NO. 1. PTEN gamma is a novel PTEN subtype protein, expressed as CUG 639 Is a translation starting point. Protein localization experimentsIt was demonstrated that PTEN gamma protein is distributed in the nucleus and is significantly enriched in the nucleolar region. The construction of the PTEN gamma specific knockout cell line proves that compared with a wild control group, the PTEN gamma specific knockout cell line has the advantages that the telomere length is obviously shortened, the cell proliferation is obviously slowed down, and the PTEN gamma plays a biological role in the telomere length maintenance. Therefore, the invention provides the application of the PTEN gamma and the related gene or the recombinant expression vector thereof in the preparation of anti-aging or tumor treatment drugs.
Papillary thyroid carcinoma (PTC) is generally a slow-growing disease with a favorable 10-year survival rate. However, about 10% of PTC cases show significant aggressiveness, with tendencies for local invasion or distant metastasis, the mechanisms of which remain unclear. This study aims to identify predictive indicators and explore new potential targets for clinical treatment, highlighting the need for novel biomarkers and therapeutic targets. We analyzed FBP1 expression in PTC tissues. Cell proliferation, apoptosis, and invasion were evaluated with and without FBP1 overexpression in PTC cells to assess FBP1's effects. We then investigated whether FBP1 reduces PTC cell tumorigenesis and metastasis by regulating HIF-1α expression. FBP1 expression was reduced in PTC samples and showed a negative correlation with T stage. In vitro experiments indicated that FBP1 acts as a hypoxia response inhibitor, regulating tumor cells. Additionally, FBP1 inhibited the proliferation, apoptosis, and invasion of thyroid cancer cells by modulating HIF-1α expression. Our results provide new insights into the role of FBP1 in PTC progression and indicate that targeting the FBP1-HIF-1α axis could be a promising therapeutic approach for this disease.
The present invention relates to a method for preparing a plaster for rheumatism and pain in muscles and bones, which belongs to the technical field of preparation methods of external Chinese medical ointment. The present ointment used for curing rheumatism has slow pain alleviating effect, short application time and strict requirements for hypersensitive skins. The present invention has the technical scheme that: angelica, earthworm, hemlock parsley, obscured homalomena rhizome, pawpaw, radix clematidis, largeleaf gentian root and radix cyathulae are put in a pan, are soaked for 3 to 10 hours with 900 to 1100 parts of teal oil by weight, and are decocted with soft fire until the medicines are dry and float off. The dregs of the medicines are removed, and then the medicines are decocted to the state that the medicine drops can not be dispersed when dropping in water. The medicines are decocted for another 30 minutes, and are taken out of water. The medicines are twirled, and the fire is extinguished if the medicines are neither too hard nor too soft. The medicines are stirred until no smoke exists, are poured in water, and soaked for a month to eliminate fire toxin. The medicines are taken out, evenly kneaded, and prepared into a plaster for rheumatism and pain in muscles and bones. The present invention has the advantages that the preparation technology is simple, and the prepared ointment has obvious effect of detumescence on early rheumatism and medium-term rheumatism, promotes blood circulation, removes blood stasis, makes qi and blood smooth, promotes the local metabolism of injury, and has rapid effect of alleviating pain. The application time is determined according to the length of the state of diseases, and the ointment can also be used for hypersensitive skins.
CONTRAINDICATIONS AND WARNINGS 

Accutane™ must not be used by patients who are or may become pregnant. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking Accutane in any amount, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected. 

Birth defects which have been documented following Accutane exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. Cases of IQ scores less than 85 with or without other abnormalities have been reported. There is an increased risk of spontaneous abortion, and premature births have been reported. 

Documented external abnormalities include: skull abnormality; ear abnormalities (including anotia, micropinna, small or absent external auditory canals); eye abnormalities (including microphthalmia); facial dysmorphia; cleft palate. Documented internal abnormalities include: CNS abnormalities (including cerebral abnormalities, cerebellar malformation, hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular abnormalities; thymus gland abnormality; parathyroid hormone deficiency. In some cases death has occurred with certain of the abnormalities previously noted.

If pregnancy does occur during treatment of a patient who is taking Accutane, Accutane must be discontinued immediately and the patient should be referred to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling.

Special Prescribing Requirements

Because of Accutane's teratogenicity and to minimize fetal exposure, Accutane is approved for marketing only under a special restricted distribution program approved by the Food and Drug Administration. This REMS is called iPLEDGE ®. Accutane must only be prescribed by prescribers who are registered and activated with the iPLEDGE Program. Accutane must only be dispensed by a pharmacy registered and activated with iPLEDGE, and must only be dispensed to patients who are enrolled and meet all the requirements of iPLEDGE (see  PRECAUTIONS).
Polycystic ovary syndrome (PCOS) is the most complex and common reproductive endocrine disease among reproductive age women. This study aimed to investigate the effects of vitamin D (Vit.D) in a PCOS mouse model induced by low dose DHEA and high-fat diet. Prepubertal female mice were divided into 4 groups randomly: control, PCOS, PCOS with low dose Vit.D(LDVD), and PCOS with high dose Vit.D(HDVD) groups (n = 10 per group). PCOS mice were administrated with high-fat diet and subcutaneous injection with 6 mg/kg/day dehydroepiandrosterone throughout the study. After the first 30 days, 1,25(OH)2D3 was intend to be administered by intraperitoneal injection for 40 consecutive days, 1.3 µg/kg/week in LDVD group, and 13 µg/kg /week in HDVD group. However, the mice in HDVD group appeared to be fatigue and anorexic after the Vit.D injections, then all died within two weeks. The body weights and testosterone levels in PCOS group were significantly higher than those in the control and LDVD groups (P < 0.001). The total cholesterol levels in the control group were lower than those in PCOS and LDVD groups (P < 0.001). Further, the ratio of liver to body weight was different among groups (P < 0.001). Our data illustrates that Vit.D has therapeutic effects on obesity and hyperandrogenemia in PCOS mouse model induced by low dose DHEA and high-fat diet. However, over dose of Vit.D is toxic. Further researches are needed to elucidate the mechanisms.
The present invention relates to composition of SOD and vegetable drugs or the extract of vegetable drugs, and a preparation method of the composition. In 1000 to 10000 active units of SOD, 1 to 50 g of vegetable drugs is contained. Vegetable drugs of the extract of vegetable drugs are added in the SOD. SOD mother liquid can reach 600 to 1000 active units/g. SOD powder can reach 4000 to 6000 active units/g. The combination application of the composition of the SOD and the vegetable drugs or the extract of vegetable drugs enhances the concentration and the effective components of the drugs. The anti-oxidation activity is enhanced by more than 6 times, the skin and mucous membrane absorption rate reaches more than 90%, and the half-life is prolonged by more than two orders of magnitude. The composition of SOD and vegetable drugs or the extract of vegetable drugs can enter cells to directly exert the function of removing free radicals, and has stronger anti-lipid peroxidation. The comprehensive drug effect is more thoroughly exerted and is much better than the drug effect of the traditional compound Chinese drugs. The composition of SOD and vegetable drugs or the extract of vegetable drugs is used for enhancing the anti-anoxia capability, exerting anti-fatigue efficiency, and enhancing exercise tolerance, is pioneering work to the human medicine career. The present invention has one of the characteristics that the composition of SOD and vegetable drugs or the extract of vegetable drugs has significant contribution to the human health career, and can cause revolution of pharmacy, biology, pharmacology and pharmacodynamics.
Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
High-mobility group box 1 (HMGB1) is a pleiotropic cytokine that propagates inflammation by its extracellular action of interacting with the receptor for advanced glycation end products (RAGE). Both HMGB1 and RAGE play multiple roles in the pathogenesis of a variety of inflammatory and autoimmune diseases. We investigated the association of five single-nucleotide polymorphisms (SNPs) of the HMGB1 gene (rs1412125, rs2249825, rs1045411, rs1060348, rs41369348) and four SNPs of the RAGE gene (rs1800624, rs1800625, rs2070600, rs3134940) with the susceptibility and clinical features of paediatric patients with IgA vasculitis (IgAV), also known as Henoch-Schönlein's purpura. This case‒control study included 103 children with IgAV (experimental group) and 150 age-matched healthy individuals (control group). The strength of the association between different groups and alleles or genotypes of HMGB1 and RAGE was estimated using odds ratios (ORs) and 95% confidence intervals (CIs). The HMGB1 polymorphisms rs41369348, rs1045411, rs2249825 and rs1412125 were associated with the development of generalized purpuric rash, and rs1412125 was associated with IgAV nephritis (IgAVN). The RAGE polymorphism rs2070600 might be linked to the development of arthritis in IgAV patients. There was no statistically significant association between the analysed polymorphisms and susceptibility to IgAV. This is the first study to propose an association between several HMGB1 and RAGE polymorphisms and different phenotypes in the clinical course of IgAV in a paediatric population. Further research on other polymorphisms of HMGB1 and RAGE should be conducted in a larger number of patients.
Cognitive Rehabilitation by computer based brain tasks, and Sham exercises focusing primary on balance and stretching. Sessions will take place twice a week for 12 weeks.
ARM 3: Meals + occupational therapy services. Participants randomized to this arm will receive 7-14 frozen meals, delivered 1x/week, for 3-months and be able to make weekly meal selections from LifeCare Alliance's full list of 40 meals. In addition to receiving nutrition education and fall prevention handouts, participants in this arm will be contacted (within 30 days of study enrollment) by one of Lifecare Alliance's occupational therapists to complete a phone screen to determine each participant's occupational therapy needs (e.g., home safety/fall risk hazards, need for durable medical equipment).
PURPOSE: An anti-diabetic composition containing citron peel extract and a method for preparing the same are provided to reduce blood glucose and to improve anti-diabetic effect. CONSTITUTION: An anti-diabetic pharmaceutical composition contains citron peel extract as an active ingredient. The citron peel extract is prepared through hot water extraction using an organic solvent. The organic solvent is phenoxy ethanol, propyl paraben, benzophenone, or ethanol. The concentration of the organic solvent is 400-1200 ug/ml. The pharmaceutical composition is manufactured in the form of a powder, granules, a capsule, a suspension, an emulsion, a syrup, or an aerosol. An anti-diabetic food composition contains the extract as an active ingredient. [Reference numerals] (AA) 2NBDG-absorption; (BB) Normal group; (CC,EE) Flesh; (DD,FF) Peel; (GG) Positive control group; (HH) Negative control group; (II) Ethanol; (JJ) Water
Methods for a touchscreen-based hand dexterity test are provided. In one aspect, a method includes providing for display, on a touchscreen, a model path. The method also includes receiving, from the touchscreen, a plurality of user touch points. The method also includes fitting the plurality of user touch points to a user path. The method also includes sampling an array of user points along the user path and sampling an array of model points along the model path. The method also includes associating each model point in the array of model points with a corresponding user point in the array of user points, wherein the associating enforces a perpendicularity constraint. The method also includes determining a test result based on the associating. Systems and machine-readable media are also provided.
The invention discloses transition metal coordination compounds with oxoglaucine as a ligand. The structural formula of the coordination compounds is represented by a formula (I), wherein M represents a bivalent metal cation which is selected from transition metal elements in the fourth period of the elements periodic table; X represents an anion of a metal salt when the metal cation is subject to a reaction in a form of metal salt, and X is nitrate or perchlorate. The coordination compounds can be synthesized with a normal-pressure solution method or a high-pressure solvent heating method. According to the invention, the inhibition effects of the transition metal coordination compounds upon various tumor cell strains are detected. As a result, a plurality of transition metal coordination compounds show stronger anti-tumor activities than oxoglaucine ligand. Therefore, the transition metal coordination compounds have good potential medicinal value, and can be used in preparations of various anti-tumor medicines.
OBJECTIVES: Intravenous opioids and local anesthetic infiltrations are traditionally used to relieve postoperative pain. With developments in the field of regional anesthesia, several methods are now available for postoperative analgesia. This study aimed to investigate the efficacy of the erector spinae plane block (ESPB) in reducing both intraoperative opioid consumption and postoperative analgesic use in patients undergoing percutaneous nephrolithotomy (PCNL).
METHODS: A total of 60 patients who underwent PCNL were divided into two groups: 30 patients who received ESPB (Group I) and 30 patients in the control group (Group II). Intraoperative and postoperative opioid usage were recorded for both groups. The pain levels of the patients were evaluated using visual analog scale (VAS) scores obtained at 1, 3, 6, 12, and 24 hours postoperatively. Postoperative satisfaction of the patients in both groups was also questioned and compared.
RESULTS: A significant difference was detected between Group I and Group II patients in terms of intraoperative opioid require-ments (p=0.00), analgesic requirements in the first 24 hours postoperatively (p=0.00), patient satisfaction status (p=0.00), and VAS scores obtained at 0, 3, 6, and 12 hours postoperatively. No significant difference was found in VAS scores at the 24th postoperative hour.
CONCLUSION: ESPB is a simple, convenient technique that can be performed under ultrasound guidance. It provides remarkable postoperative analgesia and satisfaction in patients undergoing PCNL.
Gastric, biliary and pancreatic secretions are decreased by morphine. Morphine causes a reduction in motility associated with an increase in tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone is increased to the point of spasm. The end result is constipation. Morphine can cause a marked increase in biliary tract pressure as a result of spasm of the sphincter of Oddi.
Scoliosis is the most prevalent type of spinal deformity, with a 2-3% prevalence in the general population. Moreover, surgery for scoliotic deformity may result in severe blood loss and, consequently, the need for blood transfusions, thereby increasing surgical morbidity and the rate of complications. Several antifibrinolytic drugs, such as tranexamic acid, have been regarded as safe and effective options for reducing blood loss. Therefore, the present study aimed to analyse the effectiveness of this drug for controlling bleeding when used intraoperatively and in the first 48 h after surgery. A prospective randomized study of a cohort of patients included in a mass event for scoliosis treatment using PSF was performed. Twenty-eight patients were analysed and divided into two groups: 14 patients were selected for intraoperative and postoperative use of tranexamic acid (TXA), and the other 14 were selected only during the intraoperative period. The drainage bleeding rate, length of hospital stay, number of transfused blood units, and rate of adverse clinical effects were compared. All the patients involved had similar numbers of fusion levels addressed and similar scoliosis profiles. The postoperative bleeding rate through the drain did not significantly differ between the two groups (p > 0.05). There was no significant difference in the number of transfused blood units between the groups (p = 0.473); however, in absolute numbers, patients in the control group received more transfusions. The length of hospital stay was fairly similar between the groups, with no statistically significant difference. Furthermore, the groups had similar adverse effects (p = 0.440), with the exception of nausea and vomiting, which were twice as common in the TXA group postoperatively than in the control group. No significant differences were found in the use of TXA during the first 48 postoperative hours or in postoperative outcomes.
Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA positive and received a prior poly ADP ribose polymerase (PARP) inhibitor.